BMI 28.1 is NOT eligible for Foundayo (orforglipron) therapy
A patient with BMI 28.1 kg/m² does not meet FDA-approved eligibility criteria for Foundayo unless they have at least one weight-related comorbid condition. The FDA-approved indication requires either BMI ≥30 kg/m² OR BMI ≥27 kg/m² with one or more obesity-associated comorbid conditions 1.
Eligibility Criteria for Foundayo
FDA-Approved Indications 1
Foundayo is approved for chronic weight management in combination with reduced-calorie diet and increased physical activity in:
- Adults with BMI ≥30 kg/m² (obesity), OR
- Adults with BMI ≥27 kg/m² with at least one weight-related comorbid condition
Required Weight-Related Comorbidities (if BMI 27-29.9 kg/m²)
For patients with BMI between 27-29.9 kg/m² like this case (28.1 kg/m²), at least ONE of the following must be present:
- Type 2 diabetes mellitus
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
This threshold is consistent across all FDA-approved obesity pharmacotherapy 2, 3, 4, 5, 6, 7.
Clinical Decision Algorithm
For BMI 28.1 kg/m²:
Screen for weight-related comorbidities - Check for hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, or cardiovascular disease
If ANY comorbidity present → Patient IS eligible for Foundayo
- Start with 0.8 mg once daily
- Titrate every 4 weeks: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg (maximum)
- Assess efficacy at 3 months: continue if ≥5% weight loss achieved 1
If NO comorbidities present → Patient is NOT eligible for Foundayo
- Recommend intensive lifestyle intervention (diet, exercise, behavioral therapy)
- Consider pharmacotherapy only if BMI increases to ≥30 kg/m² OR comorbidities develop
Important Clinical Considerations
Why the BMI 27 kg/m² Threshold Matters
The BMI ≥27 kg/m² with comorbidity threshold is evidence-based: patients at this level with metabolic complications derive meaningful benefit from weight loss of 5-10% in reducing cardiovascular risk, improving glycemic control, and ameliorating other obesity-related conditions 2, 4, 6.
Common Pitfall
Do not prescribe Foundayo for BMI 27-29.9 kg/m² without documented comorbidities. This represents off-label use not supported by FDA approval or clinical guidelines. The risk-benefit profile has not been established in otherwise healthy individuals with BMI <30 kg/m² 1.
Alternative Approaches for BMI 28.1 Without Comorbidities
- Intensive lifestyle intervention remains first-line: structured diet (500-750 kcal/day deficit), ≥150 minutes/week moderate-intensity physical activity, behavioral therapy 2, 4, 6
- Reassess in 3-6 months: if lifestyle intervention fails to achieve 5% weight loss, re-evaluate for emerging comorbidities that would qualify for pharmacotherapy
- Monitor for development of comorbidities: regular screening for hypertension, dyslipidemia, and dysglycemia is warranted given BMI in overweight range
Safety Monitoring if Eligible
If comorbidities are present and Foundayo is initiated, monitor monthly for first 3 months, then quarterly for 1:
- Gastrointestinal adverse effects (nausea, vomiting, diarrhea - most common)
- Weight loss efficacy (discontinue if <5% loss at 3 months on full dose)
- Volume depletion/acute kidney injury risk
- Hypoglycemia (especially if on sulfonylureas or insulin)
- Gallbladder disease